The LANDSCAPE study demonstrated that the combination of lapatinib and capecitabine achieved an ORR of 57.1% and a median time to tumor progression of 5.5 months in patients with HER2‐positive newly active brain metastasis.22 The gene discussed is ERBB2; the disease is neoplasm.